case_images: PMC10577653_01
case_images: Fundus photograph of the left eye showing foci of retinitis at the temporal aspect of the macula associated with exudates arranged in a macular star
case_images: OC-13-19-g-001.jpg
case_images: PMC10577653_01_OC-13-19-g-001.jpg
case_images: F1
case_images: Funduscopy showed vitritis with snowballs, and retinitis associated with hemorrhages at the distal ends of the temporal arcades (Figure 1 (Fig. 1)).
case_images: Fluorescein angiogram showing blocked hypofluorescence from retinal edema adjacent to areas of retinal vasculitis
case_images: OC-13-19-g-002.jpg
case_images: PMC10577653_01_OC-13-19-g-002.jpg
case_images: F2
case_images: The foci of retinitis appeared as blocked hypofluorescent lesions (Figure 2 (Fig. 2)).
case_images: Optical coherence tomography scan through the lesion showing hyperreflectivity of the inner retinal layers with posterior shadowing, consistent with retinitis
case_images: OC-13-19-g-003.jpg
case_images: PMC10577653_01_OC-13-19-g-003.jpg
case_images: F3
case_images: Optical coherence tomography scan through the lesion showed hyperreflectivity of the inner retinal layers with posterior shadowing (Figure 3 (Fig. 3)), consistent with retinitis.
case_images: Serial fundus photographs showing the response of ocular inflammation with the various treatment regimens started. The fundus at (A) baseline, (B) after 1 week of antitoxoplasmic therapy, (C) after 1 month of antituberculous therapy, and (D) after completion of antituberculous therapy
case_images: OC-13-19-g-004.jpg
case_images: PMC10577653_01_OC-13-19-g-004.jpg
case_images: F4
case_images: Compared with baseline (Figure 4A (Fig. 4)), there were decreased vitritis, retinitis, and hemorrhages (Figure 4B (Fig. 4)) with accompanying improvement in BCVA to 20/25. Within the first month of shifting to ATT, the patient developed vitreous hemorrhage (Figure 4C (Fig. 4)), which caused deterioration of his BCVA to 20/70-1. By the end of his six month course of ATT, there was a complete resolution of both ocular inflammation and vitreous hemorrhage (Figure 4D (Fig. 4)) and BCVA returned to 20/20.